LabCycle Closes The Circle
A research startup that began life in an abandoned glasshouse is tackling the estimated 5.5 million tonnes of plastic waste generated annually by the world’s bioscience and clinical labs.
A research startup that began life in an abandoned glasshouse is tackling the estimated 5.5 million tonnes of plastic waste generated annually by the world’s bioscience and clinical labs.
As environmental regulations steadily become more stringent globally, a New Zealand company is wading into the sewage ponds and waterways of Britain turning raw organic waste into high value byproducts such as biogas and fertilisers.
The overhaul of New Zealand’s publicly funded science, innovation and tech sector has kicked off with $40M of new funding for commercialisation support.
A fast growing Belgian startup is advancing the field of solid state fermentation with an innovative circular approach that converts farm biomass waste into beneficial agricultural microorganisms.
As one of the largest suppliers of energy to global markets, one might not expect Qatar to be a hotbed of climate tech activity. But the Gulf state is quietly cultivating a deep tech pillar to its economy.
A realignment of investor and sovereign interests across Europe has led to an emerging renaissance in deep tech. It is a huge opportunity for entrepreneur science researchers.
The precipitous cancellation of Australia’s Economic Accelerator (AEA) this month, alongside the redirection of $800 million in uncommitted funding, has sent a shock wave through their research, science and technology sector.
Currently, less than one percent of clothing is recycled back into new garments. A Stockholm-based deep-tech is joining the global charge towards re-processing mountains of textile waste.
Synthetic biology startup Bontia Bio focuses on creating sustainable, nature-based treatments for animal health. The New Zealand veterinary bio-pharmaceutical startup is providing non-toxic relief from flea and tick infestation for our furry friends.
Touted as “one to watch” in biotech investor circles, German biopharmaceutical company Kupando is advancing a disruptive dual approach that could both reduce solid tumours and counter infectious diseases.